Publications


Autoantibodies against type I IFNs in patients with life-threatening COVID-19. 

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group*; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. 

Science. 2020 Oct 23;370(6515):eabd4585. 

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

 

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Rodríguez-Gallego C, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group*; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group, Snow AL, Dalgard CL, Milner JD, Vinh DC, Mogensen TH, Marr N, Spaan AN, Boisson B, Boisson-Dupuis S, Bustamante J, Puel A, Ciancanelli MJ, Meyts I, Maniatis T, Soumelis V, Amara A, Nussenzweig M, García-Sastre A, Krammer F, Pujol A, Duffy D, Lifton RP, Zhang SY, Gorochov G, Béziat V, Jouanguy E, Sancho-Shimizu V, Rice CM, Abel L, Notarangelo LD, Cobat A, Su HC, Casanova JL. 

Science. 2020 Oct 23;370(6515):eabd4570.

Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016–2017 Season.

Simon B, Pichon M, Valette M, Burfin G, Richard M, Lina B and Josset L.

Viruses. 2019 Jan 28, 11, 108; doi:10.3390/v11020108.

Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.

Pichon M, Picard C, Simon B, Gaymard A, Renard C, Massenavette B, Malcus C, Monneret G, Morfin-Sherpa F, Valette M, Javouhey E, Millat G, Lina B, Josset L, Escuret V.

Antiviral Res. 2018 Oct 11;160:1-9.

Cost and Burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France.

Kramer R, Duclos A,  the VRS study group in Lyon, Lina B, Casalegno JS.

Vaccine 2018, in press.

Molecular diversity and biennial circulation of enterovirus D68: a systematic screening study in Lyon, France, 2010 to 2016.

Kramer R, Sabatier M, Wirth T, Pichon M Lina B, Schuffenecker I, Josset L.

Euro Surveill. 2018 Sep ;23(37). doi: 10.2807/1560-7917.ES.2018.23.37.1700711.

The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections.

Ferraris O, Casalegno JS, Frobert E, Bouscambert Duchamp M, Valette M, Jacquot F, Raoul H, Lina B, Ottmann M.

Viruses. 2018 Sep 17;10(9). pii: E504. doi: 10.3390/v10090504.

Synergistic Effects of Influenza and Staphylococcus aureus Toxins on Inflammation Activation and Cytotoxicity in Human Monocytic Cell Lines.

Jeannoel M, Casalegno JS, Ottmann M, Badiou C, Dumitrescu O, Lina B, Lina G.

Toxins (Basel). 2018 Jul 11;10(7). pii: E286. doi: 10.3390/toxins10070286.

Impact of the Respiratory Microbiome on Host Responses to Respiratory Viral Infection

Pichon M, Lina B and Josset L.

Vaccines. 2017 Nov 3;5(4). pii: E40. doi: 10.3390/vaccines5040040. Review

Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.

Pichon M, Gaymard A, Josset L, Valette M, Millat G, Lina B, et al.  

Antiviral Res. 2017 Sep;145:160–7. doi: 10.1016/j.antiviral.2017.07.021

Early nasopharyngeal microbial signature associated with severe influenza in children: a retrospective pilot study.

Langevin S, Pichon M, Smith E, Morrison J, Bent Z, Green R, et al.  

J Gen Virol. 2017 Sep 8; doi: 10.1099/jgv.0.000920.

La balance HA-NA des virus influenza A (H1N1).

Le Briand N., Casalegno J.S., Escuret V., Gaymard A., Lina B., Ottmann M., Frobert E.

Virologie. 2016. doi : 10.1684/vir.2016.0628

Functional balance between Neuraminidase and Hemagglutinin in influenza viruses.

Gaymard A., Le Briand N., Frobert E., Lina B., Escuret V. 

Clinical Microbiology and Infection, 2016. doi: 10.1016/j.cmi.2016.07.007.

Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).

Gaymard A., Charles A., Sabatier M., Cortay J.C., Frobert E., Picard C., Casalegno J.S., Rosa-Calatrava M., Ferraris O., Valette M., Ottmann M., Lina B., Escuret V.

Journal of Antimicrobial Chemotherapy, 2016. DOI: 10.1093/jac/dkw275

Combining high-resolution contact data with virological data to investigate influenza transmission in a tertiary care hospital.

Voirin N, Payet C, Barrat A, Cattuto C, Khanafer N, Régis C, Kim BA, Comte B, Casalegno JS, Lina B, Vanhems P.

Infect Control Hosp Epidemiol. 2015 Mar;36(3):254-60. doi: 10.1017/ice.2014.53.

Clinical presentation of severe viral encephalitis with known causative agents in children: a retrospective study on 16 patients hospitalized in a pediatric intensive care unit (2008-2011).

Adenot M, Frobert E, Blanchard G, Morel B, Perrot L, Floret D, Javouhey E.

J Child Neurol. 2014 Nov;29(11):1508-18. doi: 10.1177/0883073813513330. Epub 2014 Jan 23.

[Pandemic potential of circulating avian influenza strains sharing common features with the 1918 influenza strain].

Lina B.

Med Sci (Paris). 2014 Oct;30(10):851-3. doi: 10.1051/medsci/20143010011. Epub 2014 Oct 14 [Article in French]

Functional balance between the hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 HA D222 variants.

Casalegno JS, Ferraris O, Escuret V, Bouscambert M, Bergeron C, Linès L, Excoffier T, Valette M, Frobert E, Pillet S, Pozzetto B, Lina B, Ottmann M.

PLoS One. 2014 Aug 13;9(8):e104009. doi: 10.1371/journal.pone.0104009. eCollection 2014.

A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.

Escuret V, Collins PJ, Casalegno JS, Vachieri SG, Cattle N, Ferraris O, Sabatier M, Frobert E, Caro V, Skehel JJ, Gamblin S, Valla F, Valette M, Ottmann M, McCauley JW, Daniels RS, Lina B.

J Infect Dis. 2014 Oct 15;210(8):1260-9. doi: 10.1093/infdis/jiu244. Epub 2014 May 3.

Routes of transmission during a nosocomial influenza A(H3N2) outbreak among geriatric patients and healthcare workers.

Eibach D, Casalegno JS, Bouscambert M, Bénet T, Regis C, Comte B, Kim BA, Vanhems P, Lina B.

J Hosp Infect. 2014 Mar;86(3):188-93. doi: 10.1016/j.jhin.2013.11.009. Epub 2014 Jan 8.

Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections.

Ploin D, Chidiac C, Carrat F, Cohen B, Javouhey E, Mayaud C, Desenclos JC, Lina B, Leport C; Fluco study group.

J Clin Virol. 2013 Sep;58(1):114-9. doi: 10.1016/j.jcv.2013.05.025. Epub 2013 Jul 3.

[Description of patients with confirmed influenza A(H1N1)pdm09 admitted to an intensive care unit and identification of severity risk factors].

Payet C, Lutringer-Magnin D, Cassier P, Lina B, Argaud L, Allaouchiche B, Vanhems P.

Med Mal Infect. 2013 Feb;43(2):81-4. doi: 10.1016/j.medmal.2013.01.016. Epub 2013 Feb 28. [Article in French]

Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.

Pozo F1, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A, Community Network of Reference Laboratories for Human Influenza in Europe.

J Clin Virol. 2013 May;57(1):5-12. doi: 10.1016/j.jcv.2013.01.009. Epub 2013 Jan 31.

Pandemic A(H1N1)2009 influenza vaccination in Lyon University Hospitals, France: perception and attitudes of hospital workers.

Valour F, Bénet T, Chidiac C; Study group.

Vaccine. 2013 Jan 11;31(4):592-5. doi: 10.1016/j.vaccine.2012.11.070. Epub 2012 Dec 7.

First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013.

Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C, Guéry B, Prouvost H, Lemaire X, Paty MC, Haeghebaert S, Antoine D, Ettahar N, Noel H, Behillil S, Hendricx S, Manuguerra JC, Enouf V, La Ruche G, Semaille C, Coignard B, Lévy-Bruhl D, Weber F, Saura C, Che D; investigation team.

Euro Surveill. 2013 Jun 13;18(24). pii: 20502.

Fatal influenza A(H1N1)pdm09 encephalopathy in immunocompetent man.

Simon M, Hernu R, Cour M, Casalegno JS, Lina B, Argaud L.

Emerg Infect Dis. 2013 Jun;19(6):1005-7. doi: 10.3201/eid1906.130062.

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.

Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M, Carrat F, Duval X, Enouf V, Leport C; Bivir Study Group.

Clin Microbiol Infect. 2013 Feb;19(2):196-203. doi: 10.1111/j.1469-0691.2011.03751.x. Epub 2012 Jan 20.

Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).

Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS.

Clin Infect Dis. 2013 May;56(9):1197-205. doi: 10.1093/cid/cis1220. Epub 2013 Jan 10.

Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristics of Staphylococcus aureus associated strains.

Lamand V, Dauwalder O, Tristan A, Casalegno JS, Meugnier H, Bes M, Dumitrescu O, Croze M, Vandenesch F, Etienne J, Lina G.

Clin Microbiol Infect. 2012 Dec;18(12):E514-21. doi: 10.1111/1469-0691.12053. Epub 2012 Oct 19.

Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity.

Richard M, Erny A, Caré B, Traversier A, Barthélémy M, Hay A, Lin YP, Ferraris O, Lina B.

PLoS One. 2012;7(5):e33880. doi: 10.1371/journal.pone.0033880. Epub 2012 May 1.

High risk HPV contamination of endocavity vaginal ultrasound probes: an underestimated route of nosocomial infection?

Casalegno JS, Le Bail Carval K, Eibach D, Valdeyron ML, Lamblin G, Jacquemoud H, Mellier G, Lina B, Gaucherand P, Mathevet P, Mekki Y.

PLoS One. 2012;7(10):e48137. doi: 10.1371/journal.pone.0048137. Epub 2012 Oct 24.

T inflammatory memory CD8 T cells participate to antiviral response and generate secondary memory cells with an advantage in XCL1 production.

Jubin V, Ventre E, Leverrier Y, Djebali S, Mayol K, Tomkowiak M, Mafille J, Teixeira M, Teoh DY, Lina B, Walzer T, Arpin C, Marvel J.

Immunol Res. 2012 Jun;52(3):284-93. doi: 10.1007/s12026-012-8340-4.

H1N1 influenza A virus neuraminidase modulates infectivity in mice.

Ferraris O, Escuret V, Bouscambert M, Casalegno JS, Jacquot F, Raoul H, Caro V, Valette M, Lina B, Ottmann M.

Antiviral Res. 2012 Mar;93(3):374-80. doi: 10.1016/j.antiviral.2012.01.008. Epub 2012 Feb 1.

Increased detection of Mycoplasma pneumoniae infection in children, Lyon, France, 2010 to 2011.

Eibach D, Casalegno JS, Escuret V, Billaud G, Mekki Y, Frobert E, Bouscambert-Duchamp M, Lina B, Morfin F.

Euro Surveill. 2012 Feb 23;17(8). pii: 20094.

Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.

Delangue J, Salez N, Ninove L, Kieffer A, Zandotti C, Seston M, Lina B, Nougairede A, Charrel R, Flahault A, de Lamballerie X.

Clin Microbiol Infect. 2012 Feb;18(2):177-83. doi: 10.1111/j.1469-0691.2011.03545.x. Epub 2011 Jun 2.

The community impact of the 2009 influenza pandemic in the WHO European region: a comparison with historical seasonal data from 28 countries.

Martirosyan L, Paget WJ, Jorgensen P, Brown CS, Meerhoff TJ, Pereyaslov D, Mott JA; EuroFlu group.

BMC Infect Dis. 2012 Feb 10;12:36. doi: 10.1186/1471-2334-12-36.

Influenza vaccination of healthcare workers in acute-care hospitals: a case-control study of its effect on hospital-acquired influenza among patients.

Bénet T1, Régis C, Voirin N, Robert O, Lina B, Cronenberger S, Comte B, Coppéré B, Vanhems P.

BMC Infect Dis. 2012 Feb 1;12:30. doi: 10.1186/1471-2334-12-30.

Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009).

Amour S, Voirin N, Regis C, Bouscambert-Duchamp M, Comte B, Coppéré B, Pires-Cronenberger S, Lina B, Vanhems P.

Vaccine. 2012 Jan 20;30(5):821-4. doi: 10.1016/j.vaccine.2011.11.033. Epub 2011 Dec 2.

Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France.

Bone A, Guthmann JP, Assal A, Rousset D, Degeorges A, Morel P, Valette M, Enouf V, Jacquot E, Pelletier B, Le Strat Y, Pillonel J, Fonteneau L, van der Werf S, Lina B, Tiberghien P, Lévy-Bruhl D.

PLoS One. 2012;7(3):e33056. doi: 10.1371/journal.pone.0033056. Epub 2012 Mar 22.

Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009-2010 season.

Weil-Olivier C, Lina B.

Vaccine. 2011 Sep 16;29(40):7075-9. doi: 10.1016/j.vaccine.2011.07.018. Epub 2011 Jul 21.

Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients.

Cotte L, Voirin N, Richard C, Brochier C, Schlienger I, Lack P, Lina B, Vanhems P, Zoulim F.

Vaccine. 2011 Aug 5;29(34):5638-44. doi: 10.1016/j.vaccine.2011.06.013. Epub 2011 Jun 23.

Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.

Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B.

Antimicrob Agents Chemother. 2011 Jun;55(6):2942-52. doi: 10.1128/AAC.01699-10. Epub 2011 Mar 21.

Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.

Pelat C, Falchi A, Carrat F, Mosnier A, Bonmarin I, Turbelin C, Vaux S, van der Werf S, Cohen JM, Lina B, Blanchon T, Hanslik T.

PLoS One. 2011 May 10;6(5):e19621. doi: 10.1371/journal.pone.0019621.

Risk of influenza-like illness in an acute health care setting during community influenza epidemics in 2004-2005, 2005-2006, and 2006-2007: a prospective study.

Vanhems P, Voirin N, Roche S, Escuret V, Regis C, Gorain C, Pires-Cronenberger S, Giard M, Lina B, Najioullah F, Barret B, Pollissard L, David S, Crozet MN, Comte B, Hirschel B, Ecochard R.

Arch Intern Med. 2011 Jan 24;171(2):151-7. doi: 10.1001/archinternmed.2010.500.

Beyond the influenza-like illness surveillance: The need for real-time virological data.

Casalegno JS, Frobert E, Escuret V, Bouscambert-Duchamp M, Billaud G, Mekki Y, Schuffenecker I, Lina B, Morfin F, Valette M.

Euro Surveill. 2011 Jan 6;16(1). pii: 19756.

Factors influencing uptake of influenza vaccine amongst healthcare workers in a regional center after the A(H1N1) 2009 pandemic: lessons for improving vaccination rates.

Tagajdid MR, El Annaz H, Belefquih B, Doblali T, Casalegno JS, Mekki Y, Mrani S.

Int J Risk Saf Med. 2011;23(4):249-54. doi: 10.3233/JRS-2011-0544.

High-resolution measurements of face-to-face contact patterns in a primary school.

Stehlé J, Voirin N, Barrat A, Cattuto C, Isella L, Pinton JF, Quaggiotto M, Van den Broeck W, Régis C, Lina B, Vanhems P.

PLoS One. 2011;6(8):e23176. doi: 10.1371/journal.pone.0023176. Epub 2011 Aug 16.

[Necrotizing community-acquired pneumonia secondary to influenza a (H1N1) super-infected by an invasive group A streptococcus].

Casalegno JS, Escuret V, Celard M, Bouscambert M, Frobert E, Mekki Y, Lina G, Lina B.

Med Mal Infect. 2010 Dec;40(12):710-2. doi: 10.1016/j.medmal.2010.02.003. Epub 2010 Apr 18.[Article in French]

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.

Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C; Bivir Study Group.

PLoS Med. 2010 Nov 2;7(11):e1000362. doi: 10.1371/journal.pmed.1000362.

Genetic content of Influenza H3N2 vaccine seeds.

Bergeron C, Valette M, Lina B, Ottmann M.

PLoS Curr. 2010 Sep 5;2:RRN1165.

Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009.

Casalegno JS, Bouscambert-Duchamp M, Caro V, Schuffenecker I, Sabatier M, Traversier A, Valette M, Lina B, Ferraris O, Escuret V.

Antiviral Res. 2010 Aug;87(2):242-8.

Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.

Frobert E, Bouscambert-Duchamp M, Escuret V, Mundweiler S, Barthélémy M, Morfin F, Valette M, Gerdil C, Lina B, Ferraris O.

Curr Microbiol. 2010 Jul;61(1):25-8. doi: 10.1007/s00284-009-9571-z. Epub 2009 Dec 25.

Rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France.

Casalegno JS, Ottmann M, Duchamp MB, Escuret V, Billaud G, Frobert E, Morfin F, Lina B.

Clin Microbiol Infect. 2010 Apr;16(4):326-9. doi: 10.1111/j.1469-0691.2010.03167.x. Epub 2010 Jan 28.

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. [Article in French]

Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful?

Duchamp MB, Casalegno JS, Gillet Y, Frobert E, Bernard E, Escuret V, Billaud G, Valette M, Javouhey E, Lina B, Floret D, Morfin F.

Clin Microbiol Infect. 2010 Apr;16(4):317-21. doi: 10.1111/j.1469-0691.2010.03169.x. Epub 2010 Jan 28.

Impact of the 2009 influenza A(H1N1) pandemic wave on the pattern of hibernal respiratory virus epidemics, France, 2009.

Casalegno JS, Ottmann M, Bouscambert-Duchamp M, Valette M, Morfin F, Lina B.

Euro Surveill. 2010 Feb 11;15(6). pii: 19485.

Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance.

Ottmann M, Duchamp MB, Casalegno JS, Frobert E, Moulès V, Ferraris O, Valette M, Escuret V, Lina B.

Antivir Ther. 2010;15(5):721-6. doi: 10.3851/IMP1576.